Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $5.00

Neumora Therapeutics (NASDAQ:NMRA) had its target price boosted by Mizuho from $4.00 to $5.00 in a report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages have also issued reports on NMRA. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Bank of America reaffirmed an “underperform” rating and set a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Neumora Therapeutics currently has an average rating of “Hold” and a consensus target price of $7.14.

Neumora Therapeutics Trading Up 8.2%

NMRA opened at $1.85 on Wednesday. The firm has a market cap of $299.24 million, a price-to-earnings ratio of -1.15 and a beta of 2.75. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The stock has a fifty day moving average price of $0.88 and a 200-day moving average price of $1.28.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, equities research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Institutional Trading of Neumora Therapeutics

Several large investors have recently added to or reduced their stakes in NMRA. Capital International Investors grew its stake in Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the last quarter. Lunate Capital Ltd purchased a new position in Neumora Therapeutics during the first quarter valued at approximately $2,124,000. Graham Capital Management L.P. raised its position in Neumora Therapeutics by 1,643.7% during the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company’s stock valued at $1,162,000 after acquiring an additional 1,095,830 shares in the last quarter. AQR Capital Management LLC purchased a new position in Neumora Therapeutics during the first quarter valued at approximately $463,000. Finally, Stempoint Capital LP purchased a new position in Neumora Therapeutics during the fourth quarter valued at approximately $4,538,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.